HIMS · Hims & Hers Health, Inc.
Is HIMS setting up for a breakout, what are traders on X and the news saying, are its insiders buying, and how is the business doing? Everything Raspberry Trades measures on Hims & Hers Health, Inc., in one place.
Today's breakout radarIs HIMS setting up for a breakout?
Breakout Radar API →Not today. HIMS is not on today's radar: no tight base just under a resistance that has been tested again and again.
See the stocks that are setting up today →What are traders on X saying about HIMS?
Stock Sentiment API →Bulls: Peptides could launch within two weeks, with one post noting that in the next two weeks U.S. compounding pharmacies will be able to legally make the majority of the peptides people want; $HIMS is also hiring a Senior Director of Machine Learning at $330K–$360K to own LLM-powered clinical intake, provider support, personalization and operational workflows. The company has expanded into Germany, launched in Australia and broadened testosterone treatment options, and bulls cite $27–$28 as floor/base/support, with one buyer adding at ~$28 before Q3 and another calling it their #1 position. Bulls also point to a bullish wedge, a weekly setup 'primed' for an explosive move, and resilience: momentum has been bearish for six months but price has not declined much.
Bears: The bear case rests on peptide evidence risk: a post cites BPC-157 animal half-life under 30 minutes and a 2025 HSS Journal review finding 35 of 36 studies preclinical with no human safety data, warning supply can scale faster than evidence. Skepticism also shows up in dismissive framing ('$HIMS joke stock') and in opportunity-cost arguments favoring other names over $HIMS.
Reading from Oct 28, 2026; each post classified by AI, weighted by engagement.
What is the news saying about HIMS?
News Sentiment API →No recent news reading for HIMS. The News Sentiment API reads today's headlines on any US stock.
Are HIMS insiders buying or selling?
Insider Trading API →Open-market trades only, from SEC Form 4 filings — option exercises, tax withholding and grants are left out.
- Sold · Boughton Soleil$96K · Oct 28, 2026
- Sold · Boughton Soleil$101K · Oct 14, 2026
- Sold · Okupe Oluyemi$59K · Oct 1, 2026
- Sold · Boughton Soleil$101K · Sep 30, 2026
- Sold · Okupe Oluyemi$877K · Sep 22, 2026
How is Hims & Hers Health, Inc.'s business doing?
Financial Statements API →| Quarter ended | Revenue | vs year before | Net income | EPS |
|---|---|---|---|---|
| Jun 30, 2026 | $753.2M | +38% | −$86.3M | $-0.37 |
| Mar 31, 2026 | $608.1M | +4% | −$92.1M | $-0.40 |
| Sep 30, 2025 | $599.0M | +49% | $15.8M | $0.06 |
| Jun 30, 2025 | $544.8M | +73% | $42.5M | $0.17 |
From the company's SEC filings (10-Q and 10-K).
What does Hims & Hers Health, Inc. expect?
Company Guidance API →- Q3 2026 · revenue · 8-K filed Aug 10, 2026
“For the third quarter 2026, we expect: • Revenue of $880 million to $900 million.”
- Q3 2026 · adjusted ebitda · 8-K filed Aug 10, 2026
“• Adjusted EBITDA of $75 million to $95 million, reflecting an Adjusted EBITDA margin of 9% to 11%.”
- Q3 2026 · adjusted ebitda margin · 8-K filed Aug 10, 2026
“• Adjusted EBITDA of $75 million to $95 million, reflecting an Adjusted EBITDA margin of 9% to 11%.”
- Full year 2026 · revenue · 8-K filed Aug 10, 2026
“Raises full year 2026 revenue guidance to a range of $3.1 billion to $3.3 billion and updates Adjusted EBITDA guidance to a range of $275 million to $325 million”
Quoted from the outlook the company filed with the SEC.
Free account, no card: today's top 5 with charts, by email before the open.
Measured data, not recommendations. Not investment advice.